Mercer Global Advisors Inc. ADV Raises Stock Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Mercer Global Advisors Inc. ADV raised its stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 12.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 174,550 shares of the company's stock after acquiring an additional 18,819 shares during the quarter. Mercer Global Advisors Inc. ADV owned about 0.08% of Hims & Hers Health worth $4,221,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in HIMS. Crewe Advisors LLC bought a new position in shares of Hims & Hers Health during the fourth quarter worth $28,000. Raleigh Capital Management Inc. lifted its holdings in Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after acquiring an additional 1,100 shares in the last quarter. Blume Capital Management Inc. lifted its holdings in Hims & Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after acquiring an additional 600 shares in the last quarter. Smartleaf Asset Management LLC grew its stake in Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after acquiring an additional 1,413 shares during the period. Finally, Summit Securities Group LLC bought a new stake in shares of Hims & Hers Health in the fourth quarter worth about $38,000. Institutional investors and hedge funds own 63.52% of the company's stock.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS traded up $2.61 during trading on Wednesday, hitting $52.08. 85,963,077 shares of the company traded hands, compared to its average volume of 17,853,894. The firm has a market capitalization of $11.57 billion, a price-to-earnings ratio of 118.35 and a beta of 1.84. The business's fifty day moving average is $32.39 and its 200 day moving average is $31.82. Hims & Hers Health, Inc. has a fifty-two week low of $11.64 and a fifty-two week high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.12 by $0.08. The firm had revenue of $586.01 million during the quarter, compared to analysts' expectations of $535.21 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business's revenue was up 110.7% on a year-over-year basis. During the same period last year, the company earned $0.05 earnings per share. On average, analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Activity at Hims & Hers Health

In related news, CEO Andrew Dudum sold 50,000 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, April 29th. The shares were sold at an average price of $36.39, for a total value of $1,819,500.00. Following the sale, the chief executive officer now owns 92,103 shares of the company's stock, valued at approximately $3,351,628.17. The trade was a 35.19 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Melissa Baird sold 67,687 shares of the stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $44.71, for a total value of $3,026,285.77. Following the transaction, the chief operating officer now directly owns 706,872 shares of the company's stock, valued at approximately $31,604,247.12. This trade represents a 8.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 650,500 shares of company stock valued at $25,790,311 over the last ninety days. Corporate insiders own 17.71% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Truist Financial decreased their price objective on Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating for the company in a research report on Thursday, April 10th. Needham & Company LLC reissued a "buy" rating and set a $61.00 price objective on shares of Hims & Hers Health in a research report on Tuesday. Citigroup restated a "sell" rating and set a $30.00 price objective (up from $25.00) on shares of Hims & Hers Health in a report on Tuesday. Leerink Partners upped their target price on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a research note on Tuesday, February 25th. Finally, Canaccord Genuity Group lifted their price target on Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a research note on Wednesday, February 19th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, Hims & Hers Health presently has an average rating of "Hold" and a consensus price target of $37.67.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.